Repay (NASDAQ:RPAY – Get Free Report) and Hillstream Biopharma (NASDAQ:CNTN – Get Free Report) are both small-cap finance companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.
Profitability
This table compares Repay and Hillstream Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Repay | -49.57% | 11.03% | 4.28% |
| Hillstream Biopharma | N/A | -20.06% | -15.90% |
Insider & Institutional Ownership
82.7% of Repay shares are held by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are held by institutional investors. 12.0% of Repay shares are held by company insiders. Comparatively, 3.3% of Hillstream Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Repay | $337.81 million | 1.11 | -$256.72 million | ($2.04) | -1.93 |
| Hillstream Biopharma | $1.50 million | 123.85 | -$35.92 million | ($0.50) | -4.65 |
Hillstream Biopharma has lower revenue, but higher earnings than Repay. Hillstream Biopharma is trading at a lower price-to-earnings ratio than Repay, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations for Repay and Hillstream Biopharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Repay | 1 | 3 | 3 | 0 | 2.29 |
| Hillstream Biopharma | 1 | 0 | 0 | 0 | 1.00 |
Repay currently has a consensus price target of $5.25, indicating a potential upside of 33.59%. Given Repay’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Repay is more favorable than Hillstream Biopharma.
Risk & Volatility
Repay has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, Hillstream Biopharma has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500.
Summary
Repay beats Hillstream Biopharma on 10 of the 14 factors compared between the two stocks.
About Repay
Repay Holdings Corporation, payments technology company, provides integrated payment processing solutions to industry-oriented markets in the United States. It operates through two segments: Consumer Payments and Business Payments. The company's payment processing solutions enable consumers and businesses to make payments using electronic payment methods. It also offers a range of solutions relating to electronic payment methods, including credit and debit card processing, automated clearing house (ACH) processing, e-cash, and digital wallet services; virtual credit card processing, enhanced ACH processing, instant funding, clearing and settlement, and communication solutions; and proprietary payment channels that include Web-based, virtual terminal, online client portal, mobile application, text-to-pay, interactive voice response, and point of sale services. It serves customers primarily operating in the personal loans, automotive loans, receivables management, and business-to-business verticals through direct sales representatives and software integration partners. The company was founded in 2006 and is headquartered in Atlanta, Georgia.
About Hillstream Biopharma
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.
Receive News & Ratings for Repay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repay and related companies with MarketBeat.com's FREE daily email newsletter.
